Cite
HARVARD Citation
Jabbour, E. et al. (2019). Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 125 (15), pp. 2579-2586. [Online].